ArticlebioRxiv : the preprint server for biology2026
Maternal-fetal immune conflict contributes to male-specific impairments in a mouse model of neurodevelopmental disorders.
Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
9 authors.
Funding
Abstract
Autism spectrum disorder (ASD) arises through a combination of genetic and environmental risk factors. One environmental risk factor is maternal immune activation (MIA), wherein pathogenic infections in pregnant individuals increase the risk of ASD in the offspring, an effect seen most prevalently in males. However, the reasons that males exhibit this heightened sensitivity to MIA, and the mechanisms through which inflammatory signals traverse the maternal-fetal interface to impact the developing male embryo, remain largely mysterious. Here, we harness the poly(I:C) mouse model of neurodevelopmental disorders to uncover changes in fetal health and in the structure and composition of the maternal-fetal interface that occur within twenty-four hours of MIA. We find that 30% of embryos exhibit large-scale teratogenic abnormalities-ranging from decreased fetal weight to a lack of external sensory organ development-while 70% of embryos develop normally. Strikingly, these abnormalities only occur in a subset of males, and never in females. Single-nucleus transcriptomics revealed the robust induction of pro-inflammatory gene programs across the placentas of males exhibiting deficits following MIA, including in immune, vascular, and decidual cells. These transcriptomic changes were particularly prominent in spongiotrophoblasts, fetally derived cells that in part comprise the border between the maternal and fetal compartments of the placenta. While upregulating inflammatory pathways following MIA, spongiotrophoblasts simultaneously downregulate extracellular matrix and hormone biosynthesis pathways, concurrent with a breakdown in the structural integrity of the placenta and the accumulation of immune cells and cytokines in the embryo's amniotic fluid. One of these cytokines, IL-6, is necessary for the emergence of MIA-evoked developmental abnormalities. Our data suggest that MIA induces a rapid transition from an immunosuppressive toward a pro-inflammatory maternal-fetal interface in a subset of male embryos, leading to acute developmental deficits that are restricted to this vulnerable cohort. These data suggest that male embryos may harbor unique proteins capable of eliciting an inflammatory response at the maternal-fetal interface that, when coupled with a loss of immunosuppression due to maternal infection, derails embryonic development selectively in males.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.